Lithium, antipsychotics, and risk of psoriasis

Journal of Clinical Psychopharmacology

Volumn 29, Issue 2, 2009, Pages 134-140

  Brauchli, Yolanda B ^a   Jick, Susan S ^b   Curtin, François ^c   Meier, Christoph R ^a,b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MERCK SERONO S A   (Switzerland)

Author keywords

Antipsychotics; Case control study; Danzapine; Lithium; Psoriasis

Indexed keywords

BENZODIAZEPINE; HALOPERIDOL; LITHIUM; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OLANZAPINE; PHENOTHIAZINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ARTICLE; BODY MASS; CIGARETTE SMOKING; CONTROLLED STUDY; DATA BASE; DRUG USE; FEMALE; GENERAL PRACTICE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; PSORIASIS; RISK ASSESSMENT; TREATMENT DURATION;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CASE-CONTROL STUDIES; DATABASES AS TOPIC; DATABASES, FACTUAL; GREAT BRITAIN; HUMANS; LITHIUM COMPOUNDS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PSORIASIS; RISK; TIME FACTORS;

EID: 67649308417     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31819a4b7c     Document Type: Article

References (32)

1. Naldi L. Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy. 2004;3:121-128.
2. Raychaudhuri SP, Farber EM. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol. 2001;15:16-17.
3. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370:263-271.
4. Sabat R, Philipp S, Hoflich C, et al. Immunopathogenesis of psoriasis. Exp Dermatol. 2007;16:779-798.
5. Tagami H. Triggering factors. Clin Dermatol. 1997;15:677-685.
6. Tsankov N, Kazandjieva J, Drenovska K. Drugs in exacerbation and provocation of psoriasis. Clin Dermatol. 1998;16:333-351.
7. Abel EA, DiCicco LM, Orenberg EK, et al. Drugs in exacerbation of psoriasis. J Am Acad Dermatol. 1986;15:1007-1022.
8. Naldi L, Chatenoud L, Linder D, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol. 2005;125:61-67.
9. Naldi L, Parazzini F, Peli L, et al. Dietary factors and the risk of psoriasis. Results of an Italian case-control study. Br J Dermatol. 1996;134:101-106.
10. Fry L, Baker BS. Triggering psoriasis: the role of infections and medications. Clin Dermatol. 2007;25:606-615.
11. Yeung CK, Chan HH. Cutaneous adverse effects of lithium: epidemiology and management. Am J Clin Dermatol. 2004;5:3-8.
12. Sarantidis D, Waters B. A review and controlled study of cutaneous conditions associated with lithium carbonate. Br J Psychiatry. 1983;143:42-50.
13. Tsankov N, Angelova I, Kazandjieva J. Drug-induced psoriasis. Recognition and management. Am J Clin Dermatol. 2000;1:159-165.
14. Brauchli YB, Jick SS, Curtin F, et al. Association between beta-blockers, other antihypertensive drug and psoriasis: population-based case-control study. Br J Dermatol. 2008; 158:1299-1307.
15. Ascari-Raccagni A, Baldari U, Rossi E, et al. Exacerbation of chronic large plaque psoriasis associated with olanzepine therapy. J Eur Acad Dermatol Venereol. 2000;14:315-316.
16. Latini A, Carducci M. Psoriasis during therapy with olanzapine. Eur J Dermatol. 2003;13:404-405.
17. Fortune DG, Richards HL, Griffiths CE. Psychologic factors in psoriasis: consequences, mechanisms, and interventions. Dermatol Clin. 2005;23:681-694.
18. Garcia Rodriguez LA, Perez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol. 1998;45:419-425.
19. Wood L, Martinez C. The General Practice Research Database: role in pharmacovigilance. Drug Saf. 2004;27:871-881.
20. Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al. Validity of the General Practice Research Database. Pharmacotherapy. 2003; 23:686-689.
21. Gelfand JM, Berlin J, Van Voorhees A, et al. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol. 2003;139:1425-1429.
22. Gelfand JM, Wang X, Qing L, et al. Epidemiology and treatment patterns of psoriasis in the General Practice Research Database (GPRD). Pharmacoepidemiol Drug Saf. 2005;14(suppl):S23.
23. Gelfand JM, Weinstein R, Porter SB, et al. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol. 2005;141:1537-1541.
24. Brauchli YB, Jick SS, Curtin F, et al. Association between use of thiazolidinediones or other oral antidiabetics and psoriasis: a population based case-control study. J Am Acad Dermatol. 2008;58:421-429.
25. Osborne SF, Stafford L, Orr KG. Paroxetine-associated psoriasis. Am J Psychiatry. 2002;159:2113.
26. Hemlock C, Rosenthal JS, Winston A. Fluoxetine-induced psoriasis. Ann Pharmacother. 1992;26:211-212.
27. Cohen AD, Bonneh DY, Reuveni H, et al. Drug exposure and psoriasis vulgaris: case-control and case-crossover studies. Acta Derm Venereol. 2005;85:299-303.
28. O'Brien M, Koo J. The mechanism of lithium and beta-blocking agents in inducing and exacerbating psoriasis. J Drugs Dermatol. 2006;5: 426-432.
29. Knijff EM, Kupka RW, Ruwhof C, et al. Evidence that the immunopathogenic mechanism of lithium-induced psoriasis differs from that of regular psoriasis. Bipolar Disord. 2005;7:388-389.
30. Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol. 1985;13:450-456.
31. Drzyzga L, Obuchowicz E, Marcinowska A, et al. Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav Immun. 2006;20:532-545.
32. Aichhorn W, Whitworth AB, Weiss EM, et al. Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles? Drug Saf. 2006;29:587-598.